Gastric Cancer: Brain metastasis in patients with upper gastrointestinal cancer is associated with cancer type and lymph node metastasis.

We know that upper gastrointestinal cancer (UGC) includes adenocarcinoma, esophagus squamous cell carcinoma (ESCC) and gastric adenocarcinoma at the junction of the esophagus and gastroesophageal esophagus, all of which have a high incidence and poor prognosis worldwide.
2007, about 70,000 new cases of brain metastatic tumor (BRM) were diagnosed in patients with upper gastrointestinal cancer in the United States, so it is important to understand the incidence and prognosis of BRM.
researchers analyzed 2,348 patients with upper gastrointestinal cancer treated between January 2002 and December 2016 at anderson cancer centers in the United States, including esophagus and gastroesophageal cancer (EAC; near-end EAC, Siewert I and II), esophageal squamous cell cancer (ESCC) and gastric adenocarcinoma (GAC; gastric cancer).
researchers analyzed brM frequency and statistics on risk factors and survival rates for all patients.
results showed that 68 (2.9%) of the 2,348 patients had BRM during follow-up.
BRM rates are as follows: near-end EAC, 4.8%; Siewert I, 5.9%; Siewert II, 2.2%; Siewert III, 0.7%; ESCC: 1.2%; gastric cancer, 0%.
in multivariate analysis, in EAC patients, Siewert Type I and lymph node metastasis were not associated with risk factors for BRM.
median total survival (OS) of 68 BRM patients was only 1.16 years (95% CI 0.78-1.61).
study concluded that the pathological manifestations of gastrointestinal cancer were higher risk of BRM in patients with adenocarcinoma and near-end or lymph node metastasis, but after BRM therapy, the patient's overall survival period would be longer.
.